[Adsorption of As(â ¢) in Water by Iron-loaded Graphene Oxide-Chitosan].

Based on the principle of self-assembly, graphene oxide, chitosan, and FeCl3·6H2O were mixed to prepare graphene oxide-chitosan coated iron-composite particles (Fe@ GOCS). Batch static experiments were carried out to investigate the kinetic and thermodynamic characteristics of As(Ⅲ) adsorption, and to identify the adsorption mechanism. Results showed that the iron on the GOCS was mainly in the form of α-FeO(OH). The As(Ⅲ) adsorption capacity increased with decreasing pH, and the highest adsorption capacity occurred at pH 3. After approximately 45 h, As(Ⅲ) adsorption reached equilibrium under the conditions of pH 3 and a temperature of 298.15, 308.15, and 318.15 K. The maximum adsorption capacity was 289.4 mg·g-1 for an optimal dosage of adsorbents of 1.0 g·L-1. After five times of repeated adsorption-desorption, the adsorption capacity increased slightly. The thermodynamic parameters showed that ΔGθ<0, ΔSθ > 0, and ΔHθ>0, thus indicating that As(Ⅲ) adsorption on Fe@GOCS was a spontaneous, endothermic, and entropy-increasing reaction, and that a higher temperature was more favorable for As(Ⅲ) adsorption. The pseudo-second-order model provided a good fit of the As(Ⅲ) adsorption kinetics for Fe@GOCS. Compared to the Langmuir isotherm, As(Ⅲ) adsorption experimental data fitted better to the Freundlich and Sips models. In combination with the characterization results, it was found that ion exchange and surface complexation were the main mechanisms of As(Ⅲ) removal from aqueous solution using Fe@GOCS.

[Characteristics and Influencing Factors of Monothioarsenate Adsorption on Goethite].

The adsorption kinetic of monothioarsenate (MTA) on goethite was characterized in this study, and batch experiments were then designed to further explore the effects of arsenate, arsenite, humic acid (HA), nitrate, and phosphate on the adsorption of MTA on goethite, and to identify the adsorption mechanism. The results showed that:① When a single arsenic species was present in a solution, the adsorption equilibrium times of MTA, arsenate, and arsenite on goethite were 8, 2, and 4 h, respectively. The adsorption experimental data of these three arsenic species were well fitted to a pseudo-second-order kinetic model. The equilibrium adsorption capacities (qe) of MTA, arsenate, and arsenite on goethite were 2129.851, 3291.838, and 1788.767 mg·kg-1, respectively. When MTA coexisted with arsenate or arsenite in a solution, MTA adsorption on goethite continued to be well fitted to a pseudo-second-order kinetic model. The value of qe for MTA was significantly reduced to 1236.941 mg·kg-1 when MTA coexisted with arsenate, and to 1532.287 mg·kg-1 when MTA coexisted with arsenite, due to the fact that arsenate and arsenite competed for adsorption sites with MTA. ② With an increase in HA concentration (10-50 mg·L-1), the qe of MTA decreased gradually, due to the fact that a large number of functional groups in HA preempted the surface adsorption sites of goethite with MTA. ③ When phosphate was added into the MTA solution, the qe values of MTA, arsenate, and arsenite on goethite were reduced greatly, to 492.802, 815.782, and 303.714 mg·kg-1, respectively, which was caused by the competitive adsorption of P and As. When nitrate was added into the MTA solution, the number of electron receptors and Eh of the solution increased, leading to the qe values of MTA, arsenate, and arsenite on goethite increasing to 2211.030, 3444.023, and 1835.537 mg·kg-1, respectively.

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature.

ROS1 rearrangement has recently emerged as a new molecular subtype in non-small cell lung cancer, and is predominantly found in lung adenocarcinomas compared with other oncogenes such as EGFR, KRAS, or ALK. Patients who have both mutations are extremely rare. Here we report a 50-year-old female diagnosed with adenocarcinoma with sarcomatoid differentiation, who was shown to have EGFR and ROS1 mutations. The patient was treated surgically and received three cycles of adjuvant postoperative chemotherapy. In addition, we reviewed the previously reported cases and related literature. This presentation will provide further understanding of the underlying molecular biology and optimal treatment for non-small cell lung cancer patients with more than one driver mutation.